Predict your next investment

Academic/University
CONSUMER PRODUCTS & SERVICES | Education & Training (non-internet/mobile) / Colleges & Universities
tufts.edu

See what CB Insights has to offer

Investments

2

Partners & Customers

10

Service Providers

1

About Tufts University

Tufts is a leader in American higher education, distinctive for its success as a moderately sized university that excels at research and providing students with a personal experience. The University's unique combination of research and liberal arts attracts students, faculty and staff who thrive in their environment of curiosity, creativity and engagement.

Tufts University Headquarter Location

419 Boston Ave

Medford, Massachusetts, 2155,

United States

617-628-5000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Tufts University Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Tufts University Rank

Latest Tufts University News

Next generation mRNA vaccines exhibit excellent protective and therapeutic effects

Aug 16, 2022

Researchers around the world have been working for years on developing vaccines against different types of cancer, but without much success. Now, Tufts School of Engineering researchers think they have found one that does work. They have devised a method of targeting cancer in mice with a vaccine that is so strong and precise, it eliminates tumors and even prevents their recurrence. The cancer vaccine works similarly to COVID vaccines from Pfizer and Moderna that deliver mRNA in tiny lipid (fat molecule) bubbles that ultimately fuse with cells in the body, allowing the cells to "read" the mRNA and produce viral antigens , small fragments of the virus that activate the immune system. The cancer vaccine also delivers mRNA in tiny bubbles, but the mRNA codes for antigens found in cancer cells, and the bubbles, called lipid nanoparticles, can zero in on the lymphatic system-;where immune cells are 'trained'-;so that the response is significantly more potent. What we are doing now is developing the next generation of mRNA vaccines using lipid nanoparticle delivery technology, with the ability to target specific organs and tissues. Targeting the lymphatic system helped us to overcome many of the challenges that have faced others in developing a cancer vaccine." Qiaobing Xu, Professor, Biomedical Engineering, Tufts University The research was reported in the journal Proceedings of the National Academy of Sciences. More than 20 mRNA cancer vaccines have been enrolled to date in clinical trials, but usually much of the mRNA ends up in the liver. While antigens produced in the liver can still induce an immune response, there remains a risk of liver inflammation and damage. The response could be more effective and long-lasting if more of the vaccine were directed to the lymphatic system, where B cells, T cells and other cells of the immune system are concentrated and learn to fight off unwelcome intruders. Xu and his team had previously designed lipid nanoparticles (LNPs) that targeted gene editing packages to the brain and liver, as well as gene therapy to the lungs to reverse a genetic condition in a mouse model. Targeting is achieved by modifying the chemical structure of the lipids that make up the bubbles as well as other additives until the researchers find a combination that prefers to go to the organ of interest. In this case, they found an LNP that concentrated in the lymph nodes after they were injected subcutaneously into mice. The researchers think the LNPs collect molecules from the blood stream on their surface, and those selected molecules bind to specific receptors in the target organ. Related Stories The current LNPs used in the Pfizer COVID-19 vaccine were found to favor delivery to the liver vs. the lymphatic system by a four-to-one ratio. The Tufts team reversed that selectivity with their novel LNP to prefer lymphatic delivery over liver by a three-to-one ratio. The lymphatic system, which includes the familiar lymph nodes that often swell up during an infection, is an important target for vaccines, because that's where immunity against a foreign antigen, or in this case, a cancer antigen, is acquired. If one thinks of the body as a field of battle – against viruses, bacteria, parasites and tumors -- and the B cells and T cells as soldiers, the lymph nodes are the boot camp where the B cells and T cells are trained to be more effective against the enemy. A key element of that training is the participation of dendritic cells and macrophages – the 'drill sergeants' of the immune system that introduce the antigens to the T and B cells and help fire them up. With more vaccine going to the lymph nodes, the Tufts researchers discovered that the cancer vaccine was absorbed by about a third of the dendritic cells and macrophages. That's significantly more than obtained with conventional vaccines, and more 'drill sergeants' means more trained B and T cell 'soldiers' and a more potent response against tumors carrying the same antigen found in the vaccine. That's exactly what the researchers found. Mice with metastatic melanoma that were treated with the lymph-targeted vaccine showed significant inhibition of tumors and a 40% rate of complete response-;no tumors-;with no recurrence in the long-term when it was combined with another existing therapy that helps prevent cancer cells from suppressing an immune response. All the mice that were in complete remission prevented any new tumors from forming when injected later with metastatic tumor cells, showing that the cancer vaccine led to excellent immune memory. "Cancer vaccines have always been a challenge because tumor antigens don't always look so 'foreign' like antigens on viruses and bacteria, and the tumors can actively inhibit the immune response," said Jinjin Chen, a postdoctoral research fellow at Tufts University who is part of the Qiaobing Xu's research team. "This cancer vaccine evokes a much stronger response and is capable of carrying mRNA for both large and small antigens. We are hoping that it could become a universal platform not only for cancer vaccines, but also for more effective vaccines against viruses and other pathogens." Source:

Tufts University Investments

2 Investments

Tufts University has made 2 investments. Their latest investment was in Quanterix as part of their Series D on March 3, 2016.

CBI Logo

Tufts University Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/23/2016

Series D

Quanterix

$46M

Yes

8

Other Investors

Subscribe to see more

Subscribe to see more

10

Date

3/23/2016

Round

Series D

Other Investors

Company

Quanterix

Subscribe to see more

Amount

$46M

New?

Yes

Subscribe to see more

Co-Investors

Sources

8

10

Tufts University Partners & Customers

10 Partners and customers

Tufts University has 10 strategic partners and customers. Tufts University recently partnered with Maine Medical Center on May 5, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

5/2/2022

Partner

United States

Maine Track Celebration Honors Class of 2022.

The Maine Track program is a partnership between Maine Medical Center and Tufts formed 14 years ago to help address the shortage of doctors in Maine , provide financial assistance to aspiring medical students from Maine and develop an innovative curriculum focused on community-based education .

1

4/4/2022

Licensee

Wanda Fish Technologies collaborates with Tufts University

FoodTech Hub start-up Wanda has signed two agreements with Tufts University to advance the company 's goals in the emerging field of cultivated fish .

1

3/23/2022

Partner

United States

07:00 EDT Wanda Fish Technologies Enters Collaboration with Tufts University

NESS ZIONA , Israel , March 23 , 2022 / PRNewswire / -- FoodTech Hub start-up Wanda has signed two agreements with Tufts University to advance the company 's goals in the emerging field of cultivated fish .

4

5/27/2021

Partner

Germany

Subscribe to see more

Subscribe to see more

10

5/4/2021

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

5/2/2022

4/4/2022

3/23/2022

5/27/2021

5/4/2021

Type

Partner

Licensee

Partner

Partner

Partner

Business Partner

Country

United States

United States

Germany

United States

News Snippet

Maine Track Celebration Honors Class of 2022.

The Maine Track program is a partnership between Maine Medical Center and Tufts formed 14 years ago to help address the shortage of doctors in Maine , provide financial assistance to aspiring medical students from Maine and develop an innovative curriculum focused on community-based education .

Wanda Fish Technologies collaborates with Tufts University

FoodTech Hub start-up Wanda has signed two agreements with Tufts University to advance the company 's goals in the emerging field of cultivated fish .

07:00 EDT Wanda Fish Technologies Enters Collaboration with Tufts University

NESS ZIONA , Israel , March 23 , 2022 / PRNewswire / -- FoodTech Hub start-up Wanda has signed two agreements with Tufts University to advance the company 's goals in the emerging field of cultivated fish .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

4

10

10

Tufts University Service Providers

1 Service Provider

Tufts University has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

Tufts University Team

7 Team Members

Tufts University has 7 team members, including current President, Anthony Monaco.

Name

Work History

Title

Status

Anthony Monaco

President

Current

Christopher M. Sedore

Chief Information Officer

Current

Sally Dungan

Chief Investment Officer

Current

Mike Howard

Executive Vice President

Current

Nadine Aubry

Senior Vice President

Current

Name

Anthony Monaco

Christopher M. Sedore

Sally Dungan

Mike Howard

Nadine Aubry

Work History

Title

President

Chief Information Officer

Chief Investment Officer

Executive Vice President

Senior Vice President

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.